Evidence map›Paper›PMID 35522725›Full record

ArticleScience immunology2022

Targeting TLR4 during vaccination boosts MAdCAM-1

Alice E Denton, James Dooley, Isabella Cinti, Alyssa Silva-Cayetano, Sigrid Fra-Bido, Silvia Innocentin, Danika L Hill, Edward J Carr, Andrew N J McKenzie, Adrian Liston and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Science immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Alice E DentonImmunology Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0002-4580-3443
James DooleyImmunology Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0003-3154-4708
Isabella CintiDepartment of Immunology and Inflammation, Imperial College London, London, UK.
Alyssa Silva-CayetanoImmunology Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0003-0533-1629
Sigrid Fra-BidoImmunology Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0003-2398-5191
Silvia InnocentinImmunology Programme, Babraham Institute, Cambridge, UK.
Danika L HillImmunology Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0001-6284-7061
Edward J CarrImmunology Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0001-9343-4593
Andrew N J McKenzieMedical Research Council, Laboratory of Molecular Biology, Cambridge, UK.ORCID 0000-0001-9757-2512
Adrian ListonImmunology Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0002-6272-4085
Michelle A LintermanImmunology Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0001-6047-1996
Babraham Institute · GBImperial College London · GBMRC Laboratory of Molecular Biology · GB

Funding

Biotechnology and Biological Sciences Research Council BB/N011740/1Biotechnology and Biological Sciences Research Council BBS/E/B/000C0407Biotechnology and Biological Sciences Research Council BBS/E/B/000C0408European Research Council 637801Medical Research Council MC_U105178805Medical Research Council MR/V009591/1
6 · The paper itself

Abstract

The failure to generate enduring humoral immunity after vaccination is a hallmark of advancing age. This can be attributed to a reduction in the germinal center (GC) response, which generates long-lived antibody-secreting cells that protect against (re)infection. Despite intensive investigation, the primary cellular defect underlying impaired GCs in aging has not been identified. Here, we used heterochronic parabiosis to demonstrate that GC formation was dictated by the age of the lymph node (LN) microenvironment rather than the age of the immune cells. Lymphoid stromal cells are a key determinant of the LN microenvironment and are also an essential component underpinning GC structure and function. Using mouse models, we demonstrated that mucosal adressin cell adhesion molecule-1 (MAdCAM-1)-expressing lymphoid stromal cells were among the first cells to respond to NP-KLH + Alum immunization, proliferating and up-regulating cell surface proteins such as podoplanin and cell adhesion molecules. This response was essentially abrogated in aged mice. By targeting TLR4 using adjuvants, we improved the MAdCAM-1

Indexed as

AgingGerminal CenterToll-Like Receptor 4AgedAnimalsCell Adhesion MoleculesHumansMiceStromal CellsVaccinationCell Adhesion MoleculesTLR4 protein, humanTlr4 protein, mouseToll-Like Receptor 4

Identifiers

PMID35522725
PMCPMC7612953
OpenAlexW4229051677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.